Dr. Reddy’s sales increase by 17%
HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs had sales of $536 million in second-quarter 2014 and profits of $110 million, the company said.
Those figures represented sales growth of 17% and a 76% growth in profits over second quarter 2013. Seventy-nine percent of the company’s sales came from generic drugs, including 50% from sales in North America; sales of generics grew by 32% over last year.
During the quarter, the company filed four applications for new generics with the Food and Drug Administration, and it currently has 62 applications pending, of which 39 contain challenges to branded drug patents, and nine are potential "first-to-file" drugs for which the company would get 180 days in which to compete exclusively against the branded versions of the drugs upon FDA approval.
Teva sales increase by 2%
JERUSALEM — Teva Pharmaceutical Industries had $5.1 billion in sales and $711 million in profits in third-quarter 2013, the Israeli drug maker said.
Sales for the quarter represented a 2% increase in sales over third quarter 2012 and included $2.7 billion in U.S. sales, a 4% increase over one year ago; the company had a $79 million loss in third quarter 2012. In the United States, nearly $1.14 billion in sales came from generic drugs, up from $1.07 billion in second quarter 2012, while $1.5 billion came from the company’s specialty division, which includes its branded drugs business.
Copaxone (glatiramer acetate), an injected drug used to treat multiple sclerosis, had sales of $1.05 billion, a 1% increase over third quarter 2012, while the cancer drug Treanda (bendamustine) had sales of $184 million, a 15% increase over last year, and Teva Women’s Health had sales of $126 million, a 31% increase.
Potentially big market for adherence apps emerges
A new study by IMS Health finds that most apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, with fewer than half of them directly related to patient health and treatment, and more than half of them having fewer than 500 downloads.
With more than 43,000 health-and-wellness apps from the Apple App Store alone included in the IMS study, but a dearth of apps for elderly patients with chronic conditions, there is ample opportunity for developers to address this need. That will become especially important as health care becomes increasingly focused on patient outcomes. And this means opportunities for apps that address the ever-present issue of poor medication adherence.
According to the market research firm comScore, 143.3 million people in the United States owned smartphones in September, representing 60% of the mobile market, with Android and Apple devices constituting the majority. This also represents a potentially huge market for apps aimed at patients showing poor adherence — a problem that, according to a widely cited study by the New England Healthcare Institute, costs the healthcare system $290 billion per year. As illustrated in a special report on medication synchronization in the November issue of DSN, some vendors already are developing apps designed to improve connectivity between pharmacists and their patients.
Recently, the American Pharmacists Association listed 11 apps focused on adherence in an article on its website, including five for Apple’s iOS, two for Android and four for both platforms. Meanwhile, a study published in the Journal of the American Pharmacists Association earlier this year identified 160 adherence apps for Apple, Android and Blackberry and concluded that "Despite being untested, medication apps represent a possible strategy that pharmacists can recommend to nonadherent patients and incorporate into their practice."
This is what makes the acquisition of Catalina Health by inVentiv subsidiary Adheris so timely. As the companies said in their announcement, the combination of the two companies gives Adheris "unmatched" reach through a network that includes 30,000 pharmacies and 65% of all retail prescriptions — not to mention the ability to deliver such adherence communications as refill reminders to millions of patients via mobile.